Lipoplatin™ monotherapy

A phase II trial of second-line treatment of metastatic non-small-cell lung cancer

Alberto Ravaioli, M. Papi, E. Pasquini, M. Marangolo, B. Rudnas, M. Fantini, S. V L Nicoletti, F. Drudi, I. Panzini, E. Tamburini, L. Gianni, G. Pasini

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Lipoplatin ™ is a liposome encapsulated form of cisplatin. Phase I studies on Lipoplatin have demonstrated that the compound has an excellent toxicity profile. Therefore we performed a phase II trial in heavily pre-treated patients with advanced non-small-cell lung cancer (NSCLC), performance status 0-2 in which the primary endpoint was response rate and secondary endpoints were safety and overall survival. Nineteen patients, average age 64 years old, with stage IV NSCLC, were treated with Lipoplatin 100 mg/m2 every two weeks, as second line chemotherapy. We observed 1 partial remission (5.2%) and 3 stable diseases (15.9%). Time to progression (TTP) was 16 weeks and median overall survival (OS) was 31 weeks (7.2 months). We observed G1-G2 toxicity during chemotherapy, mainly gastrointestinal with nausea and vomiting (4 patients), asthenia (3 patients), mucositis (2 patients) and anemia (4 patients). Our phase II study does not support a more extensive use of Lipoplatin in phase III studies. An increase of dosage and a better selection of patients are mandatory to understand the real therapeufic activity of Lipoplatin.

Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalJournal of Chemotherapy
Volume21
Issue number1
Publication statusPublished - 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Asthenia
Drug Therapy
Mucositis
Survival
Liposomes
Nausea
Patient Selection
Cisplatin
Vomiting
lipoplatin
Anemia
Safety

Keywords

  • Lung cancer
  • Platinum analogues
  • Second line chemo-therapy
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology
  • Medicine(all)

Cite this

Ravaioli, A., Papi, M., Pasquini, E., Marangolo, M., Rudnas, B., Fantini, M., ... Pasini, G. (2009). Lipoplatin™ monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. Journal of Chemotherapy, 21(1), 86-90.

Lipoplatin™ monotherapy : A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. / Ravaioli, Alberto; Papi, M.; Pasquini, E.; Marangolo, M.; Rudnas, B.; Fantini, M.; Nicoletti, S. V L; Drudi, F.; Panzini, I.; Tamburini, E.; Gianni, L.; Pasini, G.

In: Journal of Chemotherapy, Vol. 21, No. 1, 2009, p. 86-90.

Research output: Contribution to journalArticle

Ravaioli, A, Papi, M, Pasquini, E, Marangolo, M, Rudnas, B, Fantini, M, Nicoletti, SVL, Drudi, F, Panzini, I, Tamburini, E, Gianni, L & Pasini, G 2009, 'Lipoplatin™ monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer', Journal of Chemotherapy, vol. 21, no. 1, pp. 86-90.
Ravaioli, Alberto ; Papi, M. ; Pasquini, E. ; Marangolo, M. ; Rudnas, B. ; Fantini, M. ; Nicoletti, S. V L ; Drudi, F. ; Panzini, I. ; Tamburini, E. ; Gianni, L. ; Pasini, G. / Lipoplatin™ monotherapy : A phase II trial of second-line treatment of metastatic non-small-cell lung cancer. In: Journal of Chemotherapy. 2009 ; Vol. 21, No. 1. pp. 86-90.
@article{6ae5ef13fa8a421c8d5b83762e0b5c8c,
title = "Lipoplatin™ monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer",
abstract = "Lipoplatin ™ is a liposome encapsulated form of cisplatin. Phase I studies on Lipoplatin have demonstrated that the compound has an excellent toxicity profile. Therefore we performed a phase II trial in heavily pre-treated patients with advanced non-small-cell lung cancer (NSCLC), performance status 0-2 in which the primary endpoint was response rate and secondary endpoints were safety and overall survival. Nineteen patients, average age 64 years old, with stage IV NSCLC, were treated with Lipoplatin 100 mg/m2 every two weeks, as second line chemotherapy. We observed 1 partial remission (5.2{\%}) and 3 stable diseases (15.9{\%}). Time to progression (TTP) was 16 weeks and median overall survival (OS) was 31 weeks (7.2 months). We observed G1-G2 toxicity during chemotherapy, mainly gastrointestinal with nausea and vomiting (4 patients), asthenia (3 patients), mucositis (2 patients) and anemia (4 patients). Our phase II study does not support a more extensive use of Lipoplatin in phase III studies. An increase of dosage and a better selection of patients are mandatory to understand the real therapeufic activity of Lipoplatin.",
keywords = "Lung cancer, Platinum analogues, Second line chemo-therapy, Toxicity",
author = "Alberto Ravaioli and M. Papi and E. Pasquini and M. Marangolo and B. Rudnas and M. Fantini and Nicoletti, {S. V L} and F. Drudi and I. Panzini and E. Tamburini and L. Gianni and G. Pasini",
year = "2009",
language = "English",
volume = "21",
pages = "86--90",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "1",

}

TY - JOUR

T1 - Lipoplatin™ monotherapy

T2 - A phase II trial of second-line treatment of metastatic non-small-cell lung cancer

AU - Ravaioli, Alberto

AU - Papi, M.

AU - Pasquini, E.

AU - Marangolo, M.

AU - Rudnas, B.

AU - Fantini, M.

AU - Nicoletti, S. V L

AU - Drudi, F.

AU - Panzini, I.

AU - Tamburini, E.

AU - Gianni, L.

AU - Pasini, G.

PY - 2009

Y1 - 2009

N2 - Lipoplatin ™ is a liposome encapsulated form of cisplatin. Phase I studies on Lipoplatin have demonstrated that the compound has an excellent toxicity profile. Therefore we performed a phase II trial in heavily pre-treated patients with advanced non-small-cell lung cancer (NSCLC), performance status 0-2 in which the primary endpoint was response rate and secondary endpoints were safety and overall survival. Nineteen patients, average age 64 years old, with stage IV NSCLC, were treated with Lipoplatin 100 mg/m2 every two weeks, as second line chemotherapy. We observed 1 partial remission (5.2%) and 3 stable diseases (15.9%). Time to progression (TTP) was 16 weeks and median overall survival (OS) was 31 weeks (7.2 months). We observed G1-G2 toxicity during chemotherapy, mainly gastrointestinal with nausea and vomiting (4 patients), asthenia (3 patients), mucositis (2 patients) and anemia (4 patients). Our phase II study does not support a more extensive use of Lipoplatin in phase III studies. An increase of dosage and a better selection of patients are mandatory to understand the real therapeufic activity of Lipoplatin.

AB - Lipoplatin ™ is a liposome encapsulated form of cisplatin. Phase I studies on Lipoplatin have demonstrated that the compound has an excellent toxicity profile. Therefore we performed a phase II trial in heavily pre-treated patients with advanced non-small-cell lung cancer (NSCLC), performance status 0-2 in which the primary endpoint was response rate and secondary endpoints were safety and overall survival. Nineteen patients, average age 64 years old, with stage IV NSCLC, were treated with Lipoplatin 100 mg/m2 every two weeks, as second line chemotherapy. We observed 1 partial remission (5.2%) and 3 stable diseases (15.9%). Time to progression (TTP) was 16 weeks and median overall survival (OS) was 31 weeks (7.2 months). We observed G1-G2 toxicity during chemotherapy, mainly gastrointestinal with nausea and vomiting (4 patients), asthenia (3 patients), mucositis (2 patients) and anemia (4 patients). Our phase II study does not support a more extensive use of Lipoplatin in phase III studies. An increase of dosage and a better selection of patients are mandatory to understand the real therapeufic activity of Lipoplatin.

KW - Lung cancer

KW - Platinum analogues

KW - Second line chemo-therapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=63049096285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63049096285&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 86

EP - 90

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 1

ER -